PHOEBE

NCT03080805 📎

Regimen

Experimental
Pyrotinib 400 mg PO daily + capecitabine 1000 mg/m2 PO BID days 1-14, q3w.
Control
Lapatinib 1250 mg PO daily + capecitabine.

Population

HER2-positive metastatic breast cancer previously treated with trastuzumab and taxane (Chinese patients).

Key finding

PHOEBE showed pyrotinib + capecitabine outperforms lapatinib + capecitabine in 2L HER2+ MBC. Major regulatory support for NMPA full approval of pyrotinib. Established pyrotinib as standard domestic TKI in China.

Source: PMID 33581774

Timeline

  • Publication: 2021 Mar

Guideline citations

  • NCCN BREAST